Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

SHSE:603392 Stock Report

Market Cap: CN¥86.1b

Beijing Wantai Biological Pharmacy Enterprise Future Growth

Future criteria checks 3/6

Beijing Wantai Biological Pharmacy Enterprise is forecast to grow earnings and revenue by 223.6% and 7.9% per annum respectively while EPS is expected to grow by 223.7% per annum.

Key information

223.6%

Earnings growth rate

223.7%

EPS growth rate

Biotechs earnings growth57.2%
Revenue growth rate7.9%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Jan 2025

Recent future growth updates

Recent updates

Does Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Have A Healthy Balance Sheet?

Jan 24
Does Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Have A Healthy Balance Sheet?

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year

Jul 26
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Jul 22
These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings

Apr 04
Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings

Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade

Apr 02
Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade

Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%

Feb 28
Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%

Earnings and Revenue Growth Forecasts

SHSE:603392 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20252,7042,970N/AN/A1
12/31/20242,425260N/AN/A1
9/30/20242,490-294-153845N/A
6/30/20242,713-1944921,500N/A
3/31/20243,3771289181,861N/A
12/31/20235,5111,2483781,538N/A
9/30/20237,5042,6001,0571,911N/A
6/30/20239,4193,7451,5712,578N/A
3/31/202310,9014,6502,3563,371N/A
12/31/202211,1854,7363,2034,133N/A
9/30/202210,8054,7772,8864,161N/A
6/30/20229,7163,9931,8473,025N/A
3/31/20228,0983,0638872,053N/A
12/31/20215,7502,0216341,682N/A
9/30/20214,3511,39833888N/A
6/30/20213,4751,15576725N/A
3/31/20212,86789666580N/A
12/31/20202,35467778468N/A
9/30/20201,95355142377N/A
6/30/20201,50436881356N/A
3/31/20201,24423934252N/A
12/31/20191,184209111273N/A
9/30/20191,09621773184N/A
6/30/20191,05426995186N/A
3/31/20191,007279-1164N/A
12/31/2018983293-38208N/A
12/31/2017950150N/A147N/A
12/31/2016844148N/A129N/A
12/31/2015681119N/A152N/A
12/31/2014596118N/A132N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603392 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 603392 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 603392 is expected to become profitable in the next 3 years.

Revenue vs Market: 603392's revenue (7.9% per year) is forecast to grow slower than the CN market (13.3% per year).

High Growth Revenue: 603392's revenue (7.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 603392's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 19:54
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Zhizhong JingChina Merchants Securities Co. Ltd.
Wei SunChina Merchants Securities Co. Ltd.